Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands

PURPOSE: Inhibition of dipeptidyl peptidase (DPP-)4 could reduce coronavirus disease 2019 (COVID-19) severity by reducing inflammation and enhancing tissue repair beyond glucose lowering. We aimed to assess this in a prospective cohort study. METHODS: We studied in 565 patients with type 2 diabetes...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Diabetes Metab Disord
Main Authors: Meijer, Rick I., Hoekstra, Trynke, van den Oever, Niels C. Gritters, Simsek, Suat, van den Bergh, Joop P., Douma, Renée A., Reidinga, Auke C., Moeniralam, Hazra S., Dormans, Tom, Smits, Mark M.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2021
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8233181/
https://ncbi.nlm.nih.gov/pubmed/34222054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40200-021-00833-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados